 |
Member
|
|
Join Date: Jan 2014
Location: Silicon Valley
Posts: 263
|
|
|
Member
Join Date: Jan 2014
Location: Silicon Valley
Posts: 263
|
Quote:
Originally Posted by southblues
Maybe we all need to take a trip to Europe.
|
You might be right . . .
The European Commission (EC) has granted orphan drug designation (ODD) to Alexion Pharmaceuticals' Soliris (eculizumab), a first-in-class terminal complement inhibitor, to treat patients with Myasthenia Gravis (MG). http://regulatoryaffairs.pharmaceuti...040814-4334013
http://www.marketwatch.com/story/eur...-mg-2014-08-01
-Mark-
|